IP Library Granted Patent US 10,806,779
Granted Patent B2
US 10,806,779 · App. 14/392,330 · Granted Oct 20, 2020

Method for preparing virosomes

Inventors: Wenyu Dong (Leiden, NL); Pieter Rijken (Leiden, NL); Mike Ugwoke (Leiden, NL)
Assignee: JANSSEN VACCINES & PREVENTION B.V.
A61K39/12A61K9/1271A61K39/145C12N7/00A61K2039/5258A61K2039/55555A61K2039/70C12N2760/16134C12N2760/16151C12N2760/16234C12N2760/16251
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,806,779
App. No.
14/392,330
Granted
Oct 20, 2020
Kind
B2
Abstract

Described are methods for preparing virosomes comprising the steps of: (a) providing an enveloped virus, and optionally inactivating the virus; (b) solubilizing the viral envelopes in a first solubilizing agent; (c) pre-solubilizing exogenous components in a second solubilizing agent; (d) adding the pre-solubilized exogenous components to the solubilized viral envelopes; and (e) reconstituting virosomal membranes by removing the solubilizing agent. According to the disclosure, the viral envelopes and the exogenous components are (pre-)solubilized at a temperature below 33° C.

Claims (27)

1. A method for preparing virosomes, the method comprising

solubilizing viral envelopes in a first solubilizing agent by stirring at a temperature of between 2-8° C. overnight;

pre-solubilizing exogenous components in a second solubilizing agent by stirring at a temperature of between 2-8° C. overnight;

adding the pre-solubilized exogenous components to the solubilized viral envelopes by stirring at a temperature below 33° C. for 30-60 minutes; and

reconstituting virosomal membranes therefrom by removing the solubilizing agent;

wherein the step of adding the pre-solubilized exogenous components to the solubilized viral envelopes does not involve the use of sonication or centrifugation.

2. The method according to claim 1 , wherein the first and second solubilizing agents are the same.

3. The method according to claim 2 , wherein the viral envelopes are solubilized using from 20-99% of a total amount of the solubilizing agent and the exogenous components are pre-solubilized using from 1-80% of the total amount of the solubilizing agent.

4. The method according to claim 1 , wherein the solubilizing agent is octaethylene glycol monododecyl ether (OEG).

5. The method according to claim 4 , wherein the solubilizing agent is used in a concentration of about 10-1000 mM.

6. The method according to claim 5 , wherein the exogenous components are exogenous lipids.

7. The method according to claim 6 , wherein the lipids are egg-derived phospholipids.

8. The method according to claim 1 , further comprising:

purifying the reconstituted virosomes.

9. The method according to claim 1 , wherein the enveloped virus is an influenza virus.

10. The method according to claim 1 , wherein the viral envelopes have been inactivated before solubilization in the first solubilizing agent.

11. The method according to claim 5 , wherein the solubilizing agent is used in a concentration of about 50-250 mM.

12. The method according to claim 7 , wherein the lipids comprise egg phosphatidylcholine.

13. A method of preparing a virosome, the method comprising:

solubilizing a viral envelope in octaethylene glycol monododecyl ether (OEG) by stirring at a temperature of between 2-8° C. overnight;

pre-solubilizing exogenous lipids in OEG by stirring at a temperature of between 2-8° C. overnight;

adding the pre-solubilized exogenous lipids to the viral envelope solubilized in OEG by stirring at a temperature below 33° C. for 30-60 minutes; and

reconstituting a virosomal membrane therefrom by removing the OEG;

wherein the step of adding the pre-solubilized exogenous lipids to the viral envelope solubilized in OEG does not involve the use of sonication or centrifugation.

14. The method according to claim 13 , wherein the viral envelopes have been inactivated before solubilization in the OEG.

15. The method according to claim 13 , wherein the OEG is utilized at a concentration of about 50-250 mM.

16. The method according to claim 13 , wherein the exogenous lipids comprise egg phosphatidylcholine.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2017
From: DONG, WENYU; RIJKEN, PIETER; UGWOKE, MIKE
To: CRUCELL HOLLAND B.V.
Reel/Frame 043434/0173 →
CHANGE OF NAME Recorded Aug 29, 2017
From: CRUCELL HOLLAND B.V.
To: JANSSEN VACCINES & PREVENTION B.V.
Reel/Frame 043709/0874 →
Priority Claims (1)
EP 13174691 · Jul 2, 2013 · regional
Continuity (1)
Related Publication 20160199480A1 · Jul 14, 2016